InnoTherapy (Korea) Performance
| 246960 Stock | KRW 9,560 170.00 1.75% |
InnoTherapy has a performance score of 6 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of -0.18, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning InnoTherapy are expected to decrease at a much lower rate. During the bear market, InnoTherapy is likely to outperform the market. InnoTherapy right now retains a risk of 1.96%. Please check out InnoTherapy downside deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if InnoTherapy will be following its current trending patterns.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in InnoTherapy are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, InnoTherapy may actually be approaching a critical reversion point that can send shares even higher in February 2025. ...more
| Total Cashflows From Investing Activities | -14.5 B |
InnoTherapy |
InnoTherapy Relative Risk vs. Return Landscape
If you would invest 870,000 in InnoTherapy on October 25, 2024 and sell it today you would earn a total of 86,000 from holding InnoTherapy or generate 9.89% return on investment over 90 days. InnoTherapy is generating 0.1733% of daily returns and assumes 1.9562% volatility on return distribution over the 90 days horizon. Simply put, 17% of stocks are less volatile than InnoTherapy, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
InnoTherapy Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for InnoTherapy's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as InnoTherapy, and traders can use it to determine the average amount a InnoTherapy's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0886
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 246960 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.96 actual daily | 17 83% of assets are more volatile |
Expected Return
| 0.17 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average InnoTherapy is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of InnoTherapy by adding it to a well-diversified portfolio.
InnoTherapy Fundamentals Growth
InnoTherapy Stock prices reflect investors' perceptions of the future prospects and financial health of InnoTherapy, and InnoTherapy fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on InnoTherapy Stock performance.
| Return On Equity | -66.34 | |||
| Return On Asset | -0.13 | |||
| Operating Margin | (6.16) % | |||
| Current Valuation | 84.92 B | |||
| Shares Outstanding | 5.04 M | |||
| Price To Sales | 97.27 X | |||
| Revenue | 507.29 M | |||
| EBITDA | (3.23 B) | |||
| Cash And Equivalents | 1.03 B | |||
| Cash Per Share | 375.11 X | |||
| Total Debt | 17.17 B | |||
| Debt To Equity | 0.56 % | |||
| Cash Flow From Operations | (3.98 B) | |||
| Total Asset | 31.88 B | |||
About InnoTherapy Performance
By analyzing InnoTherapy's fundamental ratios, stakeholders can gain valuable insights into InnoTherapy's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if InnoTherapy has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if InnoTherapy has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
InnoTherapy, Inc., engages in the development and sale of medical sealant products in South Korea. The company was founded in 2010 and is headquartered in Seoul, South Korea. InnoTherapy is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about InnoTherapy performance evaluation
Checking the ongoing alerts about InnoTherapy for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for InnoTherapy help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 507.29 M. Net Loss for the year was (5.04 B) with profit before overhead, payroll, taxes, and interest of 339.33 M. | |
| InnoTherapy has accumulated about 1.03 B in cash with (3.98 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 375.11. | |
| Roughly 28.0% of the company shares are owned by insiders or employees |
- Analyzing InnoTherapy's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether InnoTherapy's stock is overvalued or undervalued compared to its peers.
- Examining InnoTherapy's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating InnoTherapy's management team can have a significant impact on its success or failure. Reviewing the track record and experience of InnoTherapy's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of InnoTherapy's stock. These opinions can provide insight into InnoTherapy's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for InnoTherapy Stock analysis
When running InnoTherapy's price analysis, check to measure InnoTherapy's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InnoTherapy is operating at the current time. Most of InnoTherapy's value examination focuses on studying past and present price action to predict the probability of InnoTherapy's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InnoTherapy's price. Additionally, you may evaluate how the addition of InnoTherapy to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |